Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68

International Journal of Pharmaceutics

Volumn 286, Issue 1-2, 2004, Pages 69-80

  Chen, Y ^a   Zhang, G G Z ^a   Neilly, J ^a   Marsh, K ^a   Mawhinney, D ^a   Sanzgiri, Y D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABT 963; Bioavailability; Eutectic mixture; Poloxamer; Solid dispersion

Indexed keywords

ABT 963; ALCOHOL; CROSPOVIDONE; CYCLOOXYGENASE 2 INHIBITOR; DRUG CARRIER; GELATIN; LACTOSE; MACROGOL 400; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE; POLOXAMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; COOLING; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG SOLUBILITY; EVAPORATION; MELTING POINT; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLID; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CAPSULES; CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLOOXYGENASE INHIBITORS; DOGS; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; FOOD; MATERIALS TESTING; POLOXAMER; PYRIDAZINES; SOLUBILITY; SULFONES; X-RAY DIFFRACTION;

EID: 6944243071     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2004.08.009     Document Type: Article

References (16)

1. R. Bell, L. Black, R. Harries, S. Surapaneni, S. Majest, M. Nuss, G. Grayson, V. Komater, M. Coghlan, T. Kolasa, A. Stewart, and G. Carter The discovery and characterization of selective cyclooxygenase-2 inhibitors Inflamm. Res. 49 2000 S101
2. R.L. Bell, R.R. Harris, and A.O. Stewart Cox-2 inhibitors and leukotriene modulators 6th ed. D.J. Abraham Burger's Medicinal Chemistry and Drug Discovery 4 2003 John Wiley and Sons, Inc. New York 203 263
3. W.L. Chiou, and S. Riegelman Pharmaceutical applications of solid dispersion systems J. Pharm. Sci. 60 1971 1281 1302
4. D.Q.M. Craig The mechanisms of drug release from solid dispersions in water-soluble polymers Int. J. Pharm. 231 2002 131 144
5. FDA, Guidance For Industry, Dissolution Testing of Immediate Release Solid Oral Dosage Forms. August 1997.
6. A.H. Goldberg, M. Gibaldi, and J.L. Kanig Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. I. Theoretical considerations and discussion of the literature J. Pharm. Sci. 54 1965 1145 1148
7. D. Law, W. Wang, E.A. Schmitt, and M.A. Long Prediction of poly(ethylene)glycol-drug eutectic compositions using an index based on the van't Hoff equation Pharm. Res. 19 2002 315 321
8. D. Law, W. Wang, E.A. Schmitt, Y. Qiu, S. Krill, and J.J. Fort Properties of rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: the eutectic microstructure J. Pharm. Sci. 92 2003 505 515
9. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60
10. N. Passerini, B. Albertini, M.L. González-Rodríguez, C. Cavallari, and L. Rodriguez Preparation and characterization of ibuprofen-poloxamer 188 granules obtained by melt granulation Eur. J. Pharm. Sci. 15 2002 71 78
11. F. Podczeck Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT) Int. J. Pharm. 97 1993 93 100
12. K. Sekiguchi, and N. Obi Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man Chem. Pharm. Bull. 9 1961 866 872
13. A.T.M. Serajuddin Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 88 1999 1058 1066
14. S.C. Shin, and C.W. Cho Physicochemical characterizations of piroxicam-poloxamer solid dispersion Pharm. Dev. Tech. 2 1997 403 407
15. A. Wade, and P.J. Weller Handbook of Pharmaceutical Excipients 2nd ed. 1994 American Pharmaceutical Association Washington, DC
16. G.G.Z. Zhang, D. Law, E.A. Schmitt, and Y. Qiu Phase transformation considerations during process development and manufacture of solid oral dosage forms Adv. Drug Del. Rev. 56 2004 371 390